Venus Remedies has received its first patent from Mexico for ‘Vancoplus’, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. The patent has been granted from the Mexico Patent office and is valid till February 2026.
Speaking on this achievement, Dr Manu Chaudhary, Joint Managing Director and Director-Research, Venus Remedies says, “Receiving a patent grant from Mexico for our research product Vancoplus at this point in time when the frequency of MRSA strains is growing high (50-85 per cent) in Mexico is a great achievement for us. Vancoplus will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around 3 to 6 per cent of the population carries the community form of MRSA.”
As per the CDC reports published in the Journal of the American Medical Association in 2010, MRSA infections are constantly on the rise in the community and resistance against antibiotics with nearly 48 per cent of S aureus isolates were resistant to oxacillin (MRSA), and 49 per cent were resistant to levofloxacin; 33 per cent of Enterococcus faecium isolates were resistant to vancomycin and so on.
Adding further Dr Chaudhary said, “With the present scenario in mind, our novel product ‘Vancoplus’ can prove to be a life saving solution in Mexico to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin structure infections and staphylococcal endocarditis.”
Talking on the business side, Dheeraj Aggarwal, CFO, Venus Remedies said, “The value of the pharmaceutical markets in Latin America is at $50 billion, growing at the CAGR of approximately 15- 20 per cent. Mexico being the second leading market in the region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million.”
Venus Remedies is currently exporting to the various countries of LAC such as Columbia, Peru, Guatemala, Dominican Republic, Jamaica, Bahamas and the Caribbean. Its export to LAC has been growing at a rate of near 100 per cent in the past three years and LAC is contributing around 15 per cent of the total exports. He further added that receiving a patent grant from Mexico is definitely going to give a boost to our export in the region as we have already filed for market authorisation in various countries such as Mexico and few more countries in LAC.
The product vancoplus has already received seven patent grants from countries such as Australia, the US, Japan, Canada, South Africa, New Zealand and Ukraine. Patents grants for vancoplus from Europe, Brazil, and India are awaited. Vancolpus has already been successfully launched in several markets worldwide and is under registration in many countries.
EP News Bureau